uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

  • Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single dose of etranacogene dezaparvovec 
  • Etranacogene dezaparvovec also achieved secondary endpoint demonstrating statistical superiority in reduction of annualized bleeding rate compared to baseline FIX prophylactic therapy 
  • Stable and durable FIX levels with mean FIX activity of 36.9 percent of normal in full study population at 18-months, compared to a mean of 39.0 percent of normal at 6 months 
  • Manufacturing operations supporting process validation of etranacogene dezaparvovec successfully completed by uniQure 

Continue reading

City of Hope to Acquire Cancer Treatment Centers of America, Bringing Leading-Edge Cancer Research, Discovery, Compassionate Care and Advanced Treatments to More Patients, Families and Communities Nationwide 

Two nationally renowned leaders in quality, patient-centric cancer care are joining together to better serve patients with a singular focus on eradicating cancer

Combined organization will be one of the largest cancer research and treatment organizations in the country with one of the largest geographic footprints, serving approximately 115,000 patients each year

Strategic acquisition advances City of Hope’s vision to expand patient access and democratize world-class cancer care Continue reading

OncoMyx Closes $50 Million Series B to Advance a Novel Immuno-Oncology Platform that Delivers Multiple Cancer-Killing Payloads

  • Platform combines the innate immuno-stimulatory effect of the myxoma virus with anti-tumor immune stimulation that uniquely target multiple aspects of cancer immunity to treat solid tumors and hematological cancers
  • OncoMyx is developing a next generation oncolytic virus platform including the capacity for multi-arming with a nonpathogenic virus which allows for intravenous (IV) and repeat dosing
  • Proceeds of the financing will support the advancement of the company’s lead program into clinical trials with IV dosing and development of the pipeline to target critical anti-tumor immune mechanisms

Continue reading

Investments drive the growth of Arizona’s innovation sector

As Arizona continues to recover from the economic challenges caused by the pandemic, investment in our innovation sector is an essential component of our state’s current and future growth strategies. Announcements of major new investments in Arizona by global leaders including BD, Exact Sciences, Intel, and TSMC are big news today. Yet, our greatest potential for future growth comes from the young companies that are emerging in our tech and medtech sectors.Continue reading

C-Path and NICHD to Share Real-world Data to Advance Neonatal Drug Development

TUCSON, Ariz., Dec. 1, 2021 — Critical Path Institute’s (C-Path) International Neonatal Consortium (INC) today announced a seminal data-sharing collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health, as a part of a U.S. Food and Drug Administration (FDA) sponsored project to generate actionable real-world evidence (RWE) for neonatal drug development from real-world neonatal data (RWD).Continue reading

NeoLight Acquires Phoenix Technology Group

Scottsdale, AZ, Nov 17, 2021—NeoLight LLC (NeoLight), an ASU spinout and an Arizona based newborn medical device company, today announced it has acquired Phoenix Technology Group LLC (PTG), a leading provider of advanced ophthalmic imaging devices, including a telemedicine platform for retinopathy of prematurity (ROP) screening, a leading cause of blindness in premature infants. The acquisition will expand the NeoLight product portfolio to include the ocular imaging devices Phoenix ICON™, Phoenix ICON™ GO, and the telemedicine platform Phoenix CONNECT™ (previously known as FocusROP). These products provide advanced ocular imaging through lens and light innovation, providing stunning ocular images that give clinicians the needed speed, confidence, and connectivity for patient exams.Continue reading